8-K
filed June 27, 2023, 7:59 PM ET
ticker TARS
CIK 0001819790
other
confidence high
sentiment neutral
materiality 0.15
Tarsus shareholders elect three Class III directors, ratify E&Y as auditor
Tarsus Pharmaceuticals, Inc.
- Andrew Goldberg, Scott Morrison, Wendy Yarno elected to board until 2026 annual meeting.
- Director election votes: Goldberg 16.18M for, Morrison 14.67M, Yarno 16.56M; each had 4.98M broker non-votes.
- Ratification of Ernst & Young as independent auditor for FY 2023 passed with 22.17M for, 7,065 against.
- Annual meeting held June 22, 2023; 22.18M of 26.80M shares represented a quorum.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Tarsus Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-22 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-22
Exact text from the filing
Our stockholders approved the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Tarsus Pharmaceuticals, Inc. shareholders approved Election of three nominees as Class III directors at the 2023-06-22 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-22
Exact text from the filing
The following nominees were elected to serve as Class III directors for a term that will continue until the 2026 annual meeting of stockholders or until their respective successors have been duly elected and qualified.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.